Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche in-licenses USP-1 small molecule to PARP inhibitor

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 13, 2023 1:02pm

134 Views

Post# 35539643

RE:RE:RE:Roche in-licenses USP-1 small molecule to PARP inhibitor

And as previously stated, it looks like Roche/Genentech doesn't have a good understanding of the impact of the IRA on their present business model...

https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35532286

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders